m6A methylation modification and immune infiltration analysis in osteonecrosis of the femoral head.

Bioinformatic analysis Immune microenvironment Osteonecrosis of the femoral head RNA N6-methyladenosine Subtype classification

Journal

Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 02 11 2023
accepted: 28 01 2024
medline: 18 3 2024
pubmed: 16 3 2024
entrez: 16 3 2024
Statut: epublish

Résumé

Osteonecrosis of the femoral head (ONFH) is a elaborate hip disease characterized by collapse of femoral head and osteoarthritis. RNA N6-methyladenosine (m6A) plays a crucial role in a lot of biological processes within eukaryotic cells. However, the role of m6A in the regulation of ONFH remains unclear. In this study, we identified the m6A regulators in ONFH and performed subtype classification. We identified 7 significantly differentially expressed m6A regulators through the analysis of differences between ONFH and normal samples in the Gene Expression Omnibus (GEO) database. A random forest algorithm was employed to monitor these regulators to assess the risk of developing ONFH. We constructed a nomogram based on these 7 regulators. The decision curve analysis suggested that patients can benefit from the nomogram model. We classified the ONFH samples into two m6A models according to these 7 regulators through consensus clustering algorithm. After that, we evaluated those two m6A patterns using principal component analysis. We assessed the scores of those two m6A patterns and their relationship with immune infiltration. We observed a higher m6A score of type A than that of type B. Finally, we performed a cross-validation of crucial m6A regulatory factors in ONFH using external datasets and femoral head bone samples. In conclusion, we believed that the m6A pattern could provide a novel diagnostic strategy and offer new insights for molecularly targeted therapy of ONFH.

Identifiants

pubmed: 38491545
doi: 10.1186/s13018-024-04590-6
pii: 10.1186/s13018-024-04590-6
pmc: PMC10943872
doi:

Substances chimiques

6-methyladenine W7IBY2BGAX
Adenine JAC85A2161

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

183

Subventions

Organisme : National Natural Science Foundation of China
ID : 81873327
Organisme : National Natural Science Foundation of China
ID : 82004392
Organisme : National Natural Science Foundation of China
ID : 82274544

Informations de copyright

© 2024. The Author(s).

Références

Immune Netw. 2022 Mar 31;22(3):e25
pubmed: 35799706
Front Pharmacol. 2021 Nov 23;12:773758
pubmed: 34899331
Biomed Res Int. 2022 Sep 22;2022:4501186
pubmed: 36193326
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Aging (Albany NY). 2021 Dec 15;13(24):25903-25919
pubmed: 34910686
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Annu Rev Immunol. 2017 Apr 26;35:53-84
pubmed: 27912316
Front Genet. 2021 Mar 02;12:634162
pubmed: 33763115
Int Orthop. 2019 Mar;43(3):519-530
pubmed: 30328481
Cell Res. 2017 Jul;27(7):933-945
pubmed: 28585534
Br Med Bull. 2021 Mar 25;137(1):98-111
pubmed: 33454780
J Inflamm Res. 2023 Feb 28;16:879-894
pubmed: 36891172
Mol Cancer. 2020 Mar 12;19(1):53
pubmed: 32164750
Rheumatol Immunol Res. 2020 Dec 01;1(1):5-23
pubmed: 36465077
Mol Cell. 2023 Feb 2;83(3):428-441
pubmed: 36736310
J Bone Joint Surg Am. 2020 Jun 17;102(12):1084-1099
pubmed: 32282421
Aging (Albany NY). 2021 Sep 8;13(17):21134-21141
pubmed: 34496349
Nat Rev Mol Cell Biol. 2019 Oct;20(10):608-624
pubmed: 31520073
Oxid Med Cell Longev. 2022 Dec 12;2022:9744771
pubmed: 36578520
Front Oncol. 2022 Dec 22;12:1050288
pubmed: 36620557
Curr Opin Biotechnol. 2008 Aug;19(4):375-80
pubmed: 18662777
Clin Interv Aging. 2021 Jan 28;16:187-202
pubmed: 33542623
Biomed Res Int. 2019 Nov 20;2019:1302015
pubmed: 31828086
Bone Joint Res. 2022 Jan;11(1):26-28
pubmed: 35045723
Nat Immunol. 2017 Oct;18(10):1094-1103
pubmed: 28846086
Br Med Bull. 2016 Jun;118(1):33-49
pubmed: 27298230
Nat Commun. 2018 Nov 14;9(1):4772
pubmed: 30429466
Cell. 2020 Jun 25;181(7):1582-1595.e18
pubmed: 32492408
Mol Cancer. 2018 Jul 21;17(1):101
pubmed: 30031372
J Neurochem. 2018 Oct;147(2):137-152
pubmed: 29873074
J Orthop Res. 2020 Sep;38(9):2020-2030
pubmed: 32009245
Surgeon. 2023 Apr;21(2):85-98
pubmed: 34991986
BMC Bioinformatics. 2018 Nov 19;19(1):432
pubmed: 30453885
Front Cell Dev Biol. 2022 Feb 07;9:803141
pubmed: 35198565
Int Immunopharmacol. 2021 Apr;93:107345
pubmed: 33563553
Immun Ageing. 2020 Jun 12;17:19
pubmed: 32536957
Expert Opin Biol Ther. 2021 Mar;21(3):423-430
pubmed: 33297783
Oncol Rep. 2019 Aug;42(2):581-594
pubmed: 31233191
Life (Basel). 2022 Jan 26;12(2):
pubmed: 35207467
Front Endocrinol (Lausanne). 2022 Aug 10;13:957742
pubmed: 36034449
Brief Bioinform. 2021 Sep 2;22(5):
pubmed: 33594424
Am J Pathol. 2016 Nov;186(11):2987-2999
pubmed: 27648614
Inflammation. 2018 Mar;41(2):595-605
pubmed: 29247327
Nucleic Acids Res. 2019 Jul 2;47(W1):W548-W555
pubmed: 31147718
ScientificWorldJournal. 2014;2014:795624
pubmed: 25295306
J Cell Biochem. 2017 Sep;118(9):2534-2543
pubmed: 28256005

Auteurs

Weihua Fang (W)

Guangzhou University of Chinese Medicine, Guangzhou, China.

Peng Peng (P)

Guangzhou University of Chinese Medicine, Guangzhou, China.

Kun Lin (K)

Guangzhou University of Chinese Medicine, Guangzhou, China.

Fangjun Xiao (F)

Guangzhou University of Chinese Medicine, Guangzhou, China.

Wei He (W)

Guangdong Research Institute for Orthopedics and Traumatology of Chinese Medicine, Guangzhou, China.
Department of Orthopaedics, The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.

Mincong He (M)

Guangdong Research Institute for Orthopedics and Traumatology of Chinese Medicine, Guangzhou, China. min-cong.he@hotmail.com.
Department of Orthopaedics, The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China. min-cong.he@hotmail.com.

Qiushi Wei (Q)

Guangdong Research Institute for Orthopedics and Traumatology of Chinese Medicine, Guangzhou, China. weiqshi@126.com.
Department of Orthopaedics, The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China. weiqshi@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH